Navigation Links
Enigma Diagnostics Expands Its US and European Executive Management Teams
Date:11/24/2009

OXFORD, England and SAN DIEGO, Nov. 24 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today four senior appointments for its US and European offices.

Dr. Jorge Garces will lead the US team as President and CEO with Greg Hamilton, Chief Operating Officer and Chief Financial Officer, USA. Stationed at Enigma's new U.S. headquarters in San Diego, California, the headquarters will expand rapidly with a recruitment programme planned for assay development, R&D and commercial activities.

Dr. Garces joins the Enigma team after serving as Vice President of R&D and Site Operations Manager at Hologic, Inc. where he managed the R&D, clinical and manufacturing business unit in Madison, WI. During his tenure at Hologic, Dr. Garces was responsible for the product development of the company's molecular diagnostics business and clinical trial strategies, which attained FDA approval for groundbreaking Cystic Fibrosis and HPV products.

Dr. Garces holds a Ph.D. in cell and molecular biology from the City University of New York. He received his post-doctoral fellowship training at the University of Massachusetts Medical School specialising in neurobiology, biochemistry, cell and molecular biology.

Mr. Hamilton joins the Enigma team after serving as Vice President of Operations, Planning and Analysis for Hologic, Inc.'s business unit specialising in women's healthcare products. Formerly Vice President of Finance and Operations at Third Wave, he was instrumental in developing the company's strategy, leading the sale of the company to Hologic, Inc. for $582M in 2008.

Prior to Hologic, Mr. Hamilton was CFO at iLeo, Leo Burnett's former direct marketing company, where he increased its business revenue to double-digit growth and an 11x increase in profitability.

Mr. Hamilton graduated from Purdue University in 1992 with a Bachelor of Science degree in finance and earned an MBA in finance, strategy and entrepreneurship from the University of Chicago Booth School of Business.

Also joining the management team is Nick Williams, appointed as Chief Financial Officer Europe, and Darren Hall, appointed Chief Operations Officer Europe.

Mr. Williams joins Enigma with 15 years of experience in finance leadership. Most recently, he completed a second exit process with Alchemy Partners as CFO of 100m Pounds Sterling IT services group, Calyx. At Alchemy-backed industrial products group Truflo International plc, he was part of the team that achieved a 66% annual return to investors. Earlier in his career, Mr. Williams held a number of senior finance roles during a period of rapid growth with Biocompatibles International plc, a UK medical devices group. As Finance Director, he played a key role in the sale of Biocompatibles' contact lens business to Cooper Companies for over 110m pounds. Mr. Williams is a member of the Institute of Chartered Accountants in England and Wales and qualified with KPMG.

Mr. Hall joins Enigma with 12 years of extensive international experience in the healthcare and medical devices sectors. He achieved a successful track record at board level while at Graseby Plc, Smiths Industries and Biocompatibles Plc. During this time, he was heavily involved in a number of successful acquisitions and divestments. Mr. Hall has specific expertise in bringing new products to market and in developing successful operational and supply chain strategies.

Most recently, Mr. Hall was Managing Director of the Singapore based start-up Clearlab International, a subsidiary of 1800 Contacts Inc., where he led the successful business scale up. During his tenure, following the acquisition of a UK based manufacturing business; Mr. Hall led the successful transfer of manufacturing and technology from the UK to Singapore. Working closely with Mr. Williams, he successfully prepared the Clearlab business for acquisition leading to a successful exit for 1800 Contacts Inc.

John McKinley, Chairman & CEO of Enigma Diagnostics, said, "The expertise which each of Jorge, Greg, Nick and Darren bring to Enigma underpins our rapid operational and infrastructural growth across Europe and the USA, essential to delivering a leadership position in global decentralised diagnostic testing. We welcome them to our management team."

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralised and point-of-care testing providing results from a raw sample in less than 60 minutes.

The Company is targeting a number of multi-billion pound markets in the Clinical and high-value Applied Markets. Enigma's commercialisation strategy is to produce a continuous flow of market leading rapid diagnostic point-of-care instruments and assay panels, based on Enigma's innovation and proprietary technologies and underpinned by its broad intellectual property portfolio.

Enigma's majority shareholder is Porton Capital, a private equity house, which has supported Enigma's development since incorporation in 2004.

For more information visit www.enigmadiagnostics.com

Contacts

UK Contact:


Enigma Diagnostics
Deborah Cordingley
deborah.cordingley@enigmadiagnostics.com
+44 1980 590131

US Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Tamara Bright
tbright@tiberendstrategicadvisors.com
Chiara DePaolo
cdepaolo@tiberendstrategicadvisors.com




SOURCE Enigma Diagnostics Limited


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
2. The Marketing Enigma
3. New light shed on the enigma of salt intake and hypertension
4. Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office
5. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
6. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
7. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
8. Hypertension Diagnostics Announces Fiscal Year 2007 Results
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
11. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: